Dextromethorphan ameliorates effects of neonatal hypoxia on brain morphology and seizure threshold in rats.
Hypoxic injury to the brain is mediated in part by NMDA receptors. Therefore, NMDA receptor blockade with dextromethorphan (DM), a non-competitive channel blocker, was hypothesized to ameliorate injury even when given after the hypoxic insult. Rats were exposed to 8% oxygen for 3 h on postnatal day 7. Within 20 min of exposure, animals received 30 mg/kg i.p. DM or normal saline. Littermates maintained in room air for 3 h also received DM or saline. At 14 days of age, 7 days after exposure, cortical thickness and hippocampal area were measured. At 70-90 days of age, approximately two months after exposure, in a separate group of rats, seizure threshold using pentylenetetrazol (PTZ) and passive avoidance learning and retention were determined. There were no gross changes in cellular morphology and no evidence for cellular necrosis in any of the exposure groups. However, cortical thickness was decreased in animals exposed to hypoxia. DM administration prevented this decrease. Hippocampal area was unaffected. Seizure susceptibility in adulthood was increased in animals exposed to hypoxia in the neonatal period. DM prevented the decrease in seizure threshold. There was no difference in passive avoidance learning or retention as a function of neonatal exposure condition. Mild to moderate hypoxia, previously thought not to produce any histologic changes, causes significant short-term loss of cortical thickness and long-term decrease in seizure threshold. DM appears to ameliorate these effects even when given after the hypoxic insult. These results implicate the glutamate receptor system in the pathophysiology of hypoxia damage and suggest that treatment with a glutamate receptor blocker when neonatal asphyxia is suspected would help ameliorate the consequences of such an insult.
Laroia
N
N
Department of Pediatrics (Neonatology), The Children's Hospital at Strong, Rochester, NY 14642, USA.
McBride
L
L
Baggs
R
R
Guillet
R
R
D000375:Aging / Q000502:physiology*; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D001362:Avoidance Learning / Q000187:drug effects / Q000502:physiology*; D001921:Brain / Q000187:drug effects / Q000254:growth & development* / Q000473:pathology; D002540:Cerebral Cortex / Q000254:growth & development; D003915:Dextromethorphan / Q000494:pharmacology*; D006624:Hippocampus / Q000254:growth & development; D006801:Humans; D002534:Hypoxia, Brain / Q000473:pathology / Q000503:physiopathology* / Q000517:prevention & control; D008297:Male; D010433:Pentylenetetrazole; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000502:physiology; D012016:Reference Values; D012640:Seizures / Q000139:chemically induced / Q000503:physiopathology*
D016194:Receptors, N-Methyl-D-Aspartate; D003915:Dextromethorphan; D010433:Pentylenetetrazole